Masahito Kawazu

Chiba Cancer Center — Japan

Medicine · Health Sciences

36h-index5.6kcitations383works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(103), Immune Cell Function and Interaction(68), CAR-T cell therapy research(44), Immunotherapy and Immune Responses(40), Cancer Genomics and Diagnostics(39)

Publications383 total

Selective MYC 5′ amplification in postirradiation/lymphedema-associated angiosarcoma
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2026
Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Supplementary Figures from High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects
2025Open Access
Supplementary Tables from High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects
2025Open Access
Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer
Cancer Immunology Research·2025· 2 citedOpen Access
Liver-specific amino acid metabolism impacts on efficacy of cancer immunotherapy
2025Open Access
Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture
British Journal of Cancer·2025Open Access
The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes
JHEP Reports·2025Open Access
Data from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Tables from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S9 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S7 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S10 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S8 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S2 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
Supplementary Figure S1 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy
2025Open Access
page 1 of 20Next →

Frequent Co-authors

Hiroyuki Mano(34), Toshihide Ueno(30), Shinya Kojima(18), Mineo Kurokawa(15), Seishi Ogawa(11), Manabu Soda(11), Yosuke Togashi(10), Shigeru Chiba(10), Takahiko Yasuda(10), Yoshihiro Yamashita(10), Susumu Goyama(10), Eirin Sai(9), Hiroyoshi Nishikawa(8), Masahiro Nakagawa(8), Motoshi Ichikawa(8), Hisamaru Hirai(7), Kazutaka Fukumura(7), Azusa Yamato(7), Takashi Asai(7), Akihito Kawazoe(6)